Medication Guide App

Generic Spiriva Availability

Spiriva is a brand name of tiotropium, approved by the FDA in the following formulation(s):

SPIRIVA (tiotropium bromide monohydrate - powder;inhalation)

Has a generic version of Spiriva been approved?

No. There is currently no therapeutically equivalent version of Spiriva available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Spiriva. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
    Patent 6,777,423
    Issued: August 17, 2004
    Inventor(s): Rolf; Banholzer & Peter; Sieger & Christian; Kulinna & Michael; Trunk & Manfred; Graulich & Peter; Specht & Helmut; Meissner & Andreas; Mathes
    Assignee(s): Boehringer Ingelheim Pharma KG
    Crystalline monohydrate of (1&agr;,2&bgr;,4&bgr;,5&agr;,7&bgr;)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.
    Patent expiration dates:
    • September 24, 2021
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
    Patent 6,908,928
    Issued: June 21, 2005
    Inventor(s): Banholzer; Rolf & Sieger; Peter & Kulinna; Christian & Trunk; Michael & Graulich; Manfred & Specht; Peter & Meissner; Helmut & Mathes; Andreas
    Assignee(s): BI Pharma KG.
    Crystalline monohydrate of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.
    Patent expiration dates:
    • September 24, 2021
      ✓ 
      Patent use: TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • September 24, 2021
      ✓ 
      Patent use: FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Inhalable powder containing tiotropium
    Patent 7,070,800
    Issued: July 4, 2006
    Inventor(s): Bechtold-Peters; Karoline & Walz; Michael & Boeck; Georg & Doerr; Rolf
    Assignee(s): Boehringer Ingelheim Pharma KG
    The invention relates to powdered preparations containing tiotropium for inhalation, processes for preparing them as well as their use in preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.
    Patent expiration dates:
    • January 22, 2022
      ✓ 
      Patent use: FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
      ✓ 
      Drug product
  • Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
    Patent 7,309,707
    Issued: December 18, 2007
    Inventor(s): Bender; Helmut & Graebner; Hagen & Schindler; Konrad & Trunk; Michael & Walz; Michael
    Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG
    The invention relates to a crystalline micronisate of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.
    Patent expiration dates:
    • September 24, 2021
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
    Patent 7,642,268
    Issued: January 5, 2010
    Inventor(s): Bender; Helmut & Graebner; Hagen & Schindler; Konrad & Trunk; Michael & Walz; Michael
    Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG
    The invention relates to a crystalline micronisate of (1 α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide, processes for preparing it and its use for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition with an anticholinergic activity.
    Patent expiration dates:
    • September 24, 2021
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Dry powder inhaler
    Patent 7,694,676
    Issued: April 13, 2010
    Inventor(s): Wachtel; Herbert
    Assignee(s): Boehringer Ingelheim GmbH
    An inhaler for inhaling powdered pharmaceutical compositions from capsules includes: a lower part; a plate which can be latched to the lower part and with which the lower part can be closed off; a capsule holder for receiving the capsules, this holder being adapted to be lowered into the lower part; a mouthpiece latchable to the plate; a lid which covers the mouthpiece in a closed position and latches it by means of a closure element, the lower part, the plate, the mouthpiece and the lid being hinged together by means of a single joint; and an actuating member which can be moved out a resting position and thereby interacts with at least one pin which can be made to pierce the capsule holder.
    Patent expiration dates:
    • March 12, 2027
      ✓ 
      Drug product
  • Method for the administration of an anticholinergic by inhalation
    Patent 8,022,082
    Issued: September 20, 2011
    Inventor(s): Zierenberg; Bernd
    Assignee(s): Boehringer Ingelheim Pharma GmbH & Co., KG
    An inhalation kit comprising: (a) an inhaler displaying a flow resistance of about 0.01 to 0.1 √{square root over (kPa)} min/L; and (b) an inhalable powder comprising tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 to 500 μm, and a method of administering an inhalable powder containing tiotropium in admixture with a physiologically acceptable excipient with an average particle size of between 10 μm to 500 μm, the method comprising actuating an inhaler a flow resistance of about 0.01 to 0.1 √{square root over (kPa)} min/L containing the inhalable powder.
    Patent expiration dates:
    • January 19, 2026
      ✓ 
      Patent use: ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE
      ✓ 
      Drug product
  • Process for preparing powder formulations
    Patent RE38912
    Issued: December 6, 2005
    Inventor(s): Walz; Michael & Boeck; Georg
    Assignee(s): Boehringer Ingelheim Pharma KG
    The invention relates to a new process for producing powdered preparations for inhalation.
    Patent expiration dates:
    • October 11, 2021
      ✓ 
      Drug product
  • Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
    Patent RE39820
    Issued: September 4, 2007
    Inventor(s): Banholzer; Rolf & Bauer; Rudolf & Reichl; Richard
    Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG
    Compounds of the formula of which, in exemplary compounds, the thienyl group is attached via the 2-position and; (a) A is 3α-(6β, 7β-epoxy)-tropanyl methobromide and R1 is 2-thienyl; (b) A is 3α-(6, 7dehydro)-tropanyl methobromide and R1 is 2-thienyl; (c) A is 3β-tropanyl methobromide and R1 is 2-thienyl; and, (d) A is 3α-(N-isopropyl)-nortropanyl methobromide and R1 is cyclopentyl. There are anticholinergics. Administered by inhalation, they are useful for the treatment of chronic obstructive bronchitis or slight to moderately severe asthma. Administered by the intravenous or oral routes, they are useful for the treatment of vagally induced sinus bradycardia.
    Patent expiration dates:
    • January 30, 2018
      ✓ 
      Patent use: FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
      ✓ 
      Drug substance
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web1)